Servier to Buy Day One Biopharmaceuticals for $2.5 Billion to Lead in Childhood Brain Cancer

French pharma leader Servier acquires U.S. biotech Day One in a $2.5B cash deal to become #1 in pediatric low-grade glioma and expand rare cancer treatments for children and adults. Expected close: Q2 2026.